<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2609211075
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Steglujan
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SITAGLIPTIN PHOSPHATE,ERTUGLIFLOZIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        226.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SCHERING-PLOUGH LABO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SCHERING-PLOUGH LABO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10B
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Steglujan is</p><p>Steglujan contains two active substances, ertugliflozin and sitagliptin.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ertugliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sitagliptin belongs to a group of medicines called DPP-4 (dipeptidyl peptidase-4) inhibitors.</p><p>&nbsp;</p><p>What Steglujan is used for</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steglujan lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steglujan can be used instead of taking both ertugliflozin and sitagliptin as separate tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steglujan can be used alone or with some other medicines that lower blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Steglujan.</p><p>&nbsp;</p><p>How Steglujan works</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ertugliflozin works by blocking the SGLT2 protein in your kidneys. This causes blood sugar to be removed in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sitagliptin helps to increase the levels of insulin produced after a meal. It also lowers the amount of sugar made by your body.</p><p>&nbsp;</p><p>What is type 2 diabetes?</p><p>Type 2 diabetes is a condition in which your body does not make enough insulin or the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, like heart disease, kidney disease, blindness and poor circulation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Steglujan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ertugliflozin or sitagliptin or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist, or nurse before and while taking Steglujan if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had yeast infections of the vagina or penis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had serious heart disease or if you have had a stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had a disease of the pancreas (such as pancreatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have type 1 diabetes. Steglujan should not be used to treat this condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take other diabetes medicines: you are more likely to get low blood sugar with certain medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; might be at risk of dehydration (for example, if you are taking medicines that increase urine production [diuretics] or lower blood pressure or if you are over 65 years old). Ask about ways to prevent dehydration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood. These medical conditions can increase your chance of getting pancreatitis (see section 4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat contact a doctor or the nearest hospital straight away. These symptoms could be a sign of &ldquo;diabetic ketoacidosis&rdquo; &ndash; a problem you can get with diabetes because of increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood, seen in tests. The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a lower limb amputation.</p><p>&nbsp;</p><p>It is important to check your feet regularly and adhere to any other advice regarding foot care and adequate hydration given by your healthcare professional. You should notify your doctor immediately if you notice any wounds or discolouration, or if you experience any tenderness or pain in your feet. Some studies indicate that taking ertugliflozin may have contributed to an increase in cases of lower limb amputation (mainly of the toe).</p><p>&nbsp;</p><p>Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving sitagliptin (see section 4).</p><p>&nbsp;</p><p>Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell. These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier&rsquo;s gangrene which destroys the tissue under the skin. Fournier&rsquo;s gangrene has to be treated immediately.</p><p>&nbsp;</p><p>When this medicine is used in combination with insulin or medicines that increase insulin release from the pancreas, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your insulin or other medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>Urine glucose</p><p>Because of how Steglujan works, your urine will test positive for sugar (glucose) while you are on this medicine.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Children and adolescents below 18 years should not take this medicine. It is not known if this medicine is safe and effective when used in children and adolescents under 18 years of age.</p><p>&nbsp;</p><p>Other medicines and Steglujan</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines which increase urine production (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines that lower the amount of sugar in your blood, such as insulin or medicines that increase insulin release from the pancreas.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). The level of digoxin in your blood may need to be checked if you are taking it with Steglujan.</p><p>If any of the above apply to you (or you are not sure), tell your doctor.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not known if Steglujan can harm your unborn baby. You should not take this medicine during pregnancy.</p><p>&nbsp;</p><p>It is not known if this medicine passes into breast milk. Talk with your doctor about the best way to feed your baby if you take Steglujan. You should not use this medicine if you are breast-feeding or plan to breast-feed.</p><p>&nbsp;</p><p>Driving and using machines</p><p>This medicine has no or negligible influence on the ability to drive and use machines. However, dizziness and drowsiness have been reported with sitagliptin, which may affect your ability to drive or use machines. Do not drive or use any tools or machines if you feel dizzy while taking Steglujan.</p><p>&nbsp;</p><p>Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating or changes in vision and may affect your ability to drive and use machines.</p><p>&nbsp;</p><p>Steglujan contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>How much to take</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Steglujan is one tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose of Steglujan that you take will depend on your condition and the amount of ertugliflozin and sitagliptin needed to control your blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will prescribe the right dose for you. Do not change your dose unless your doctor has told you to.</p><p>&nbsp;</p><p>Taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet; if you have difficulties with swallowing the tablet can be broken or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one tablet every morning. Try to take it at the same time; this will help you remember to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablet with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Steglujan.</p><p>&nbsp;</p><p>If you take more Steglujan than you should</p><p>If you take too much Steglujan, talk to a doctor or pharmacist straight away.</p><p>&nbsp;</p><p>If you forget to take Steglujan</p><p>If you forget a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and go back to your regular schedule.</p><p>&nbsp;</p><p>Do not take a double dose (two doses on the same day) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Steglujan</p><p>Do not stop taking this medicine without talking to your doctor. Your blood sugar levels may increase if you stop the medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Stop taking Steglujan and contact a doctor straight away if you notice any of the following serious side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas (pancreatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.</p><p>If you notice any of the serious side effects above, stop taking this medicine and contact a doctor straight away.</p><p>&nbsp;</p><p>Contact a doctor or the nearest hospital straight away if you have any of the following serious side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)</strong></p><p>These are the signs of diabetic ketoacidosis (see also section &ldquo;Warnings and precautions&rdquo;):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast and deep breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual sleepiness or tiredness</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat</p><p>This may occur regardless of blood glucose level. Your doctor may decide to temporarily or permanently stop your treatment with Steglujan.</p><p>&nbsp;</p><p>Necrotising fasciitis of the perineum or Fournier&rsquo;s gangrene (not known, cannot be estimated from the available data)</p><p>A serious soft tissue infection of the genitals or the area between the genitals and the anus (see section &ldquo;Warnings and precautions&rdquo; for symptoms).</p><p>&nbsp;</p><p>If you notice any of the side effects above, contact a doctor or the nearest hospital straight away.</p><p>&nbsp;</p><p>Contact your doctor as soon as possible if you notice the following side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Dehydration (losing too much water from your body; common, may affect up to 1 in 10 people)</strong></p><p>Symptoms of dehydration include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, light-headed, or weak, especially when you stand up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&nbsp;</p><p>You may be more likely to get dehydrated if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take medicines that increase your urine production (diuretics) or lower blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are 65 years or older</p><p>&nbsp;</p><p>Low blood sugar (hypoglycaemia; common)</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you have any of the symptoms or signs below. The doctor may lower the dose of your insulin or other diabetes medicine.</p><p>&nbsp;</p><p>Signs and symptoms of low blood sugar may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hunger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling jittery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&nbsp;</p><p>If you notice any of the side effects above, contact your doctor as soon as possible.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal yeast infection (thrush)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar</p><p>&nbsp;</p><p>Common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeast infections of the penis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in urination, including urgent need to urinate more often, in larger amounts, or at night</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of urea in your blood</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of total and bad cholesterol (called LDL - a type of fat in your blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of red blood cells in your blood (called haemoglobin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flatulence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the hands or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stuffy or runny nose and sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoarthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arm or leg pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea/vomiting</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes related to kidney function (such as &lsquo;creatinine&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&nbsp;</p><p>Rare</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of platelets</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems (sometimes requiring dialysis) and including a condition called tubulointerstitial nephritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; interstitial lung disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bullous pemphigoid (a type of skin blister)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC), SFDA By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.</p><p>&nbsp;</p><p>&nbsp; Store below 300C.&nbsp; Store in the original package</p><p>&nbsp;</p><p>Do not use this medicine if the packaging is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are ertugliflozin and sitagliptin.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Steglujan 5 mg/100 mg film-coated tablet contains 5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Steglujan 15 mg/100 mg film-coated tablet contains 15 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate (anhydrous), croscarmellose sodium, sodium stearyl fumarate (E487), magnesium stearate (E470b).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet coat: hypromellose (E464), hydroxypropyl cellulose (E463), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172), carnauba wax (E903).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Steglujan 5 mg/100 mg film-coated tablets (tablets) are beige, 12.0 x 7.4 mm, almond-shaped, film-coated tablets debossed with “554” on one side and plain on the other side.
•	Steglujan 15 mg/100 mg film-coated tablets (tablets) are brown, 12.0 x 7.4 mm, almond-shaped, film-coated tablets debossed with “555” on one side and plain on the other side.
 
Steglujan is available in Alu/PVC/PA/Alu blisters. The pack sizes are 14, 28, 30, 84, 90 and 98 film- coated tablets in non-perforated blisters and 30x1 film-coated tablets in perforated unit dose blisters.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Schering-Plough Labo NV</p><p>Industriepark 30</p><p>Heist-op-den-berg, B-2220</p><p>Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2020


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.



This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو </strong><strong>ستيقلوجان</strong><br />يحتوي ستيقلوجان على مادتين فعّالتين هما إرتوقليفلوزين و سيتاقلبتين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إرتوقليفلوزين ؛ ينتمي إلى مجموعة من الأدوية تُسمّى مثبطات الناقل المشارك للصوديوم/جلوكوز-2 (SGLT2) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; سيتاقلبتين الذي ينتمي إلى مجموعة من الأدوية تُسمّى مثبطات 4-بيبتيداز ثنائي البيبتيديل &ldquo;DPP-4&rdquo;.</p><p dir="RTL"><strong>دواعي استخدام</strong> <strong>ستيقلوجان</strong></p><p dir="RTL">&bull; يقلل ستيقلوجان من مستويات السكر في الدم لدى المرضى البالغين (الذين تتراوح أعمارهم بين 18 سنة وما فوق) المصابين بمرض السكري من النوع 2.</p><p dir="RTL">&bull; يمكن استخدام ستيقلوجان بدلًا من استخدام كلٍّ من إرتوقليفلوزين و سيتاقلبتين كأقراص منفصلة.</p><p dir="RTL">&bull; يمكن استخدام ستيقلوجان بمفرده أو مع بعض الأدوية الأخرى التي تُخفض نسبة السكر في الدم.</p><p dir="RTL">&bull; تحتاج إلى الاستمرار في الالتزام بخطة الغذاء والتمارين أثناء تناول ستيقلوجان.</p><p dir="RTL"><br /><strong>طريقة عمل ستيقلوجان </strong></p><p dir="RTL">&bull; يعمل إرتوقليفلوزين عن طريق تثبيط عمل بروتين SGLT2 في الكليتين، مما يؤدي إلى طرح سكّر الدم في البول.</p><p dir="RTL">&bull; يعمل سيتاقلبتين على زيادة مستويات الأنسولين الذي يُفرز بعد تناول الوجبة. كما أنه يقلل من كمية السكر التي يصنعها جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو مرض السكري من النوع 2</strong></p><p dir="RTL">مرض السكري من النوع الثاني هو حالة مرضية يصبح فيها جسمك غير قادر على إنتاج كمية كافية من الأنسولين أو أنّ الأنسولين الذي ينتجه الجسم لا يعمل كما يجب. يمكن أن يقوم جسمك أيضًا بإنتاج الكثير من السكر. عندما يحدث هذا، يتراكم السكر (الجلوكوز) في الدم مما قد يؤدي إلى مشاكل طبية خطيرة، مثل أمراض القلب وأمراض الكلى والعمى وضعف الدورة الدموية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ستيقلوجان </strong><br />&bull; إذا كنت تعاني من حساسية تجاه إرتوقليفلوزين أو سيتاقلبتين أو تجاه أيّ من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل وأثناء استخدام ستيقلوجان إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull; تعاني أو سبق وعانيت من عدوى فطريّة في المهبل أو القضيب.</p><p dir="RTL">&bull; سبق وأن عانيت من مرض خطير في القلب أو أُصبت بسكتة دماغية.</p><p dir="RTL">&bull; تعاني أو سبق وعانيت من مرض في البنكرياس (مثل التهاب البنكرياس).</p><p dir="RTL">&bull; تعاني من مرض السكري من النوع 1 ، &nbsp;يجب عدم استخدام ستيقلوجان لعلاج هذه الحالة.</p><p dir="RTL">&bull; تتناول أدوية أخرى لعلاج مرض السكري: إذ قد تنخفض نسبة السكر في الدم لديك عند استخدام ستيقلوجان مع بعض الأدوية الأخرى.</p><p dir="RTL">&bull; مُعرّض لخطر حدوث الجفاف (على سبيل المثال، إذا كنت تتناول أدوية تزيد من إنتاج البول [مدرات البول] أو أدوية لعلاج ضغط الدم المُرتفع أو إذا كان عمرك يزيد عن 65 عامًا). اسأل طبيبك عن طرق تجنّب حدوث الجفاف.</p><p dir="RTL">&bull; تعاني أو سبق وعانيت من حصى المرارة أو الاعتماد على الكحول أو مستويات عالية جدا من الدهون الثلاثية (شكل من أشكال الدهون) في الدم. يمكن أن تزيد هذه الحالات الطبية من فرصة الإصابة بالتهاب البنكرياس (انظر الفقرة رقم 4).</p><p dir="RTL">&bull; تتعرض لفقدان الوزن السريع، والشعور بالمرض أو حدوث المرض، وألم البطن، والعطش الشديد، والتنفس السريع والعميق، والارتباك، والنعاس أو التعب غير العادي، وظهور رائحة حلوة لنَفَسِك (رائحة الفاكهة) ؛ أو الإحساس بطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرَق لديك، راجع طبيبك أو أقرب مستشفى على الفور. قد تكون هذه الأعراض علامة على حدوث &quot;الحُماض الكيتوني السكري&quot; - وهي مشكلة يمكن أن تحدث بسبب مرض السكري نتيجة زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم،<br />والتي تظهر في الفحوصات. قد يزداد خطر الإصابة بالحُماض الكيتوني السكّري مع الصيام لفترات طويلة، والإفراط في استهلاك الكحول، والجفاف، والتخفيض المفاجئ في جرعة الأنسولين، أو مع الحاجة لكميات أعلى من الأنسولين بسبب الخضوع لجراحة كبرى أو التعرّض لمرض خطير.</p><p dir="RTL">&bull; بتر في الطرف السفلي.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">من المهم فحص قدميك بانتظام والالتزام بأي نصيحة أخرى تتعلق برعاية القدم والترطيب الكافي الذي يمنحه أخصائي الرعاية الصحية. يجب عليك إخطار طبيبك على الفور إذا لاحظت أي جروح أو تغير اللون، أو إذا كنت تعاني من أي ألم في قدميك. تشير بعض الدراسات إلى أن تناول إرتوقليفلوزين قد يكون ساهم في زيادة حالات بتر الأطراف السفلية بشكل رئيسي من إصبع القدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث حالات التهاب البنكرياس لدى المرضى الذين يتلقون العلاج &nbsp;بسيتاقلبتين (انظر الفقرة رقم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور إذا كنت تعاني من الألم أو أو الاحمرار أو تورم الأعضاء التناسلية أو المنطقة الواقعة بين الأعضاء التناسلية والإصابة بالحمى أو الشعور بتوعك عام. يمكن أن تكون هذه الأعراض علامة على عدوى نادرة ولكنها خطيرة أو حتى مهددة للحياة، تسمى غرغرينا فورنييه التي تدمر الأنسجة تحت الجلد. غرغرينا فورنييه يجب أن تعالج على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث انخفاض في نسبة السكر في الدم (نقص سكر الدم) عند استخدام هذا الدواء بالاشتراك مع الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس. قد يقلل الطبيب لك جرعة الأنسولين أو أي دواء آخر تتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سكّر البول </strong></p><p dir="RTL">سيُظهر فحص البول لديك نتيجة إيجابيّة لوجود السكر أثناء تناولك لهذا الدواء، وذلك بسبب الطريقة التي يعمل بها ستيقلوجان.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا عدم تناول هذا الدواء. إذ من غير المعروف&nbsp; إذا كان هذا الدواء آمنًا وفعالًا عند استخدامه لدى هذه الفئة العُمريّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى مع </strong><strong>ستيقلوجان </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرًا أو قد تتناول أيّ أدوية أخرى.<br />أخبر طبيبك على وجه الخصوص إذا كنت تتناول:</p><p dir="RTL">&bull; أدوية تزيد من إنتاج البول (مُدرّات البول).</p><p dir="RTL">&bull; أدوية أخرى تُقلل من كمية السكر في الدم، مثل الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس.</p><p dir="RTL">&bull; الديجوكسين (دواء يستخدم لعلاج اضطراب ضربات القلب ومشاكل القلب الأخرى). قد يلزم فحص مستوى الديجوكسين في دمك إذا كنت تتناوله مع ستيقلوجان.</p><p dir="RTL">إذا كانت أيّ من الحالات المذكورة أعلاه تنطبق عليك (أو إذا كنت لست متأكدًا)، أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مُرضعًا ، تعتقدين أنّك قد تكونين حاملًا ، أو تخططين لإنجاب طفل ، فعليك استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">من غير المعروف إذا كان ستيقلوجان يضر بجنينك. لذا يجب تجنّب استخدام هذا الدواء أثناء الحمل.</p><p dir="RTL">من غير المعروف إذا كان هذا الدواء يُفرز في حليب الثدي. استشيرى طبيبك حول أفضل طريقة لتغذية &nbsp;طفلك الرضيع إذا كنتِ تتناولين ستيقلوجان. يجب عليك عدم استخدام هذا الدواء إذا كنت ترضعين رضاعة طبيعية أو تخططين لإرضاع طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا الدواء ليس له تأثيرٌ يُذكر على القدرة على القيادة واستخدام الآلات. ومع ذلك، فقد تم الإبلاغ عن حدوث &nbsp;الدوخة والنعاس مع استخدام ستيقلوجان ، مما قد يؤثر على قدرتك على القيادة أو استخدام الآلات. تجنّب القيادة واستخدام أي أدوات أو آلات إذا شعرت بالدوار أثناء تناول ستيغلوجان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي تناول هذا الدواء إلى جانب الأنسولين أو الأدوية التي تزيد من إفراز الأنسولين من البنكرياس إلى انخفاض مستويات السكر في الدم (نقص سكر الدم)، مما قد يتسبب في أعراض مثل الارتعاش أو التعرق أو تغيرات في الرؤية وقد يؤثر على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>ستيقلوجان</strong><strong> يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 مليمول صوديوم 23 ملغ لكل قرص ، أي &quot;خالي من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء حسب ارشادات الطبيب أو الصيدلي تمامًا. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.<br />&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&bull; الجرعة الموصى بها من ستيقلوجان هي حبة واحدة مرة واحدة في اليوم.</p><p dir="RTL">&bull; تعتمد جرعة ستيقلوجان التي تتناولها على حالتك وكمية إرتوقليفلوزين و سيتاقليبتين اللازمة للتحكم في نسبة السكر في الدم لديك.</p><p dir="RTL">&bull; سيصف لك الطبيب الجرعة المناسبة. لا تُغير الجرعة إلا إذا أخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول الدواء</strong></p><p dir="RTL">&bull; قم بابتلاع القرص كاملًا ؛ إذا كنت تواجه صعوبة في ابتلاع القرص، فيمكنك كسره أو سحقه.</p><p dir="RTL">&bull; تناول قرص واحد كل صباح. حاول أن تتناوله في نفس الوقت من كلّ يوم ؛ سيساعدك ذلك على تذكر موعد الجرعة.</p><p dir="RTL">&bull; يمكنك أن تتناول الأقراص مع أو بدون طعام.</p><p dir="RTL">&bull; تحتاج إلى الاستمرار في اتباع خطة الطعام والتمارين أثناء تناول ستيقلوجان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت من ستيقلوجان أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت من ستيقلوجان أكثر مما يجب، تحدث إلى الطبيب أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول إحدى جرعات ستيقلوجان &nbsp;</strong></p><p dir="RTL">إذا نسيت أن تتناول إحدى الجرعات، خذها حالما تتذكرها. ولكن ، إذا كان الوقت قد حان لتناول جرعتك التالية ، فتجاوز الجرعة الفائتة وعد إلى جدولك المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة (جرعتان في اليوم نفسه) للتعويض عن جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول ستيقلوجان </strong><br />لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك. قد تزيد مستويات السكر في الدم إذا توقفت عن تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية ، يمكن أن يُسبب هذا الدواء أعراضًا جانبيّة وإن كانت لا تحدث لدى جميع من يتناوله.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>توقّف عن تناول ستيقلوجان وراجع الطبيب على الفور إذا لاحظت أي</strong><strong>ًّا</strong><strong> من الأعراض الجانبية الخطرة التالية:</strong></p><p dir="RTL">&bull; ألم حاد ومستمر في منطقة البطن (منطقة المعدة) الذي قد يصل إلى ظهرك مع أو بدون الغثيان والقيء ، لأن هذه يمكن أن تكون علامات التهاب البنكرياس.</p><p dir="RTL">&bull; تفاعل تحسسي خطير (تكرار حدوثه غير معروف) ، يشمل الطفح الجلدي ، والشرى ، والألومنيوم على الجلد/تقشّر الجلد وتورم في الوجه والشفتين واللسان والحلق الذي قد يُسبّب صعوبة في التنفس أو البلع. قد يصف لك الطبيب دواء لعلاج رد الفعل التّحسّسي وأدوية مختلفة لمرض السكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب</strong><strong> </strong><strong>اللفافة</strong><strong> </strong><strong>النخري</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>غرغرينا</strong><strong> </strong><strong>فورنييه</strong><strong> </strong><strong>&nbsp;(غير</strong><strong> </strong><strong>معروف،</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقديره</strong><strong> </strong><strong>من</strong><strong> </strong><strong>البيانات</strong><strong> </strong><strong>المتاحة):</strong></p><p dir="RTL">عدوى خطيرة في الأنسجة الرخوة في الأعضاء التناسلية أو المنطقة الواقعة بين الأعضاء التناسلية (انظر قسم &quot; التحذيرات والاحتياطات&quot; للأعراض&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية الخطرة المذكورة أعلاه، فتوقف عن تناول هذا الدواء وراجع الطبيب فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>راجع الطبيب أو اذهب إلى أقرب مستشفى على الفور إذا ظهرت لديك أيّا من الأعراض الجانبية الخطرة التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحُماض الكيتوني السُّكَّرِيّ (نادر، قد يؤثر على 1 من بين 1،000 شخص)</strong></p><p dir="RTL">الأعراض التالية تُمثل علامات الحماض الكيتوني السكري (انظر أيضا فقرة &quot;التحذيرات والاحتياطات&quot;):</p><p dir="RTL">&bull; زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم</p><p dir="RTL">&bull; فقدان الوزن السريع</p><p dir="RTL">&bull; الغثيان أو التقيؤ</p><p dir="RTL">&bull; ألم البطن</p><p dir="RTL">&bull; العطش الشديد</p><p dir="RTL">&bull; تنفس سريع وعميق</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; النعاس أو التعب غير المعتاد &nbsp;</p><p dir="RTL">&bull; رائحة حلوة لنَفَسِك (رائحة الفواكه) ، وطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرق لديك.</p><p dir="RTL">قد يحدث هذا بغض النظر عن مستوى السكر في الدم. قد يقرر طبيبك إيقاف علاجك بستيقلوجان بشكل مؤقت أو دائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه، راجع الطبيب أو أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>راجع الطبيب في أقرب وقت ممكن إذا تعرّضت للأعراض الجانبية التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجفاف (فقدان كمية كبيرة من الماء من جسمك؛ شائع، قد يؤثر على 1 من بين 10 أشخاص)</strong></p><p dir="RTL">تشمل أعراض الجفاف ما يلي:</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; الشعور بالدوار ، أو الدوخة ، أو الضعف ، خاصة عند الوقوف</p><p dir="RTL">&bull; الإغماء</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون أكثر عرضة للإصابة بالجفاف إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى</p><p dir="RTL">&bull; تتناول الأدوية التي تزيد من إنتاج البول (مُدرّات البول) أو تلك الخافضة لضغط الدم</p><p dir="RTL">&bull; تبلغ 65 سنة من العمر أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض نسبة السكر في الدم (نقص سكر الدم ؛ شائع)</strong></p><p dir="RTL">سيخبرك الطبيب عن كيفية علاج انخفاض سكر الدم وماذا تفعل إذا كان لديك أي من الأعراض أو العلامات أدناه. قد يقلل الطبيب من جرعة الأنسولين أو أي دواء آخر مضاد للسكري تستخدمه.<br />&nbsp;</p><p dir="RTL">قد تشمل علامات وأعراض انخفاض نسبة السكر في الدم ما يلي:</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">&bull; النعاس</p><p dir="RTL">&bull; الهيجان</p><p dir="RTL">&bull; الجوع</p><p dir="RTL">&bull; الدوخة</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; التعرق</p><p dir="RTL">&bull; الشعور بالتوتر الشديد</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; تسارع نبضات القلب</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه، راجع طبيبك في أسرع وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وتشمل الأعراض الجانبية الأخرى: </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong></p><p dir="RTL">&bull; عدوى الفطريات المهبلية (القلاع)</p><p dir="RTL">&bull; انخفاض سكر الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">&bull; عدوى الفطريات في القضيب</p><p dir="RTL">&bull; التغيرات في التبول ، بما في ذلك الحاجة المُلحّة إلى التبول المُتكرّر ، بكميات أكبر ، أو في الليل</p><p dir="RTL">&bull; العطش</p><p dir="RTL">&bull; الحكّة المهبلية</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية اليوريا في دمك</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية الكولسترول الكلّي والسيئ (تسمى LDL - نوع من الدهون في دمك)</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية كريات الدم الحمراء في الدم (تسمى الهيموقلوبين)</p><p dir="RTL">&bull; الإمساك</p><p dir="RTL">&bull; ظهور غازات في البطن</p><p dir="RTL">&bull; تورم في اليدين أو الساقين</p><p dir="RTL">&bull; أنفلونزا</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">&bull; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">&bull; احتقان أو سيلان الأنف والتهاب الحلق</p><p dir="RTL">&bull; التهاب عظمي مِفصلي</p><p dir="RTL">&bull; ألم الذراع أو الساق</p><p dir="RTL">&bull; غثيان/تقيّؤ</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على 1 من بين 100 شخص)</strong></p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغييرات متعلقة بوظائف الكلى (مثل &quot;كرياتينين&quot;)</p><p dir="RTL">&bull; ألم أثناء التبوّل</p><p dir="RTL">&bull; ألم المعدة</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; النعاس</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; الدوخة</p><p dir="RTL">&bull; الحكّة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong></p><p dir="RTL">&bull; انخفاض عدد الصفائح الدموية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكرار حدوثها غير معروف (لا يمكن تقدير وتيرة الحدوث من البيانات المتاحة)</strong></p><p dir="RTL">&bull; مشاكل في الكلى (تتطلب في بعض الأحيان غسيل الكلى) وبما في ذلك حالة تسمى التهاب الكلية الأنبوبي الخلالي</p><p dir="RTL">&bull; الم المفاصل</p><p dir="RTL">&bull; ألم عضلي</p><p dir="RTL">&bull; ألم في الظهر</p><p dir="RTL">&bull; مرض الرئة الخلالي</p><p dir="RTL">&bull; شبيه الفُقّاع الفُقّاعي (وهو نوع من الألومنيوم الجلدية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبيّة</strong><br />إذا أُصبت بأيّ أعراض جانبية ، تحدث مع طبيبك أو الصيدلي أو الممرض. يتضمن ذلك أيّ أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;. يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على شريط الألومنيوم والكرتون بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية. يُحفظ في العبوة الأصلية .</p><p dir="RTL">لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات الفتح.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات ستيقلوجان</p><p dir="RTL">&bull; المواد الفعالة هي إرتوقليفلوزين و سيتاقليبتين</p><p dir="RTL">o يحتوي كل قرص من أقراص ستيقلوجان مُغلّف تركيزه 5 ملغم /100 ملغم على 5 ملغم من إرتوقليفلوزين (على شكل إرتوقليفلوزينإل-بيروجلوتاميك أسيد) و 100 ملغم سيتاقلبتين (على شكل &nbsp;سيتاقلبتينفوسفات مونوهايدرات).</p><p dir="RTL">o يحتوي كل قرص من أقراص ستيقلوجان مُغلّف تركيزه 15 ملغم /100 ملغم على 15 ملغم من إرتوقليفلوزين (على شكل إرتوقليفلوزينإل-بيروجلوتاميك أسيد) و 100 ملغم سيتاقلبتين (على شكل سيتاقلبتينفوسفات مونوهايدرات).</p><p dir="RTL">&bull; المكونات الأخرى هي:</p><p dir="RTL">o لُبّ القرص: السليلوز دقيق التبلور (E460)، فوسفات هيدروجين الكالسيوم (لا مائي)، صوديوم كروس كارميلوز، فومارات ستيريل الصوديوم (E487)، ستيرات المغنيسيوم (E470b).</p><p dir="RTL">o طبقة الغشاء الرقيق: هيبروميلوز (E464)، هيدروكسي بروبيل السليلوز(E463)، ثاني أكسيد التيتانيوم (E171)، أكسيد لحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)، أكسيد الحديد &nbsp;الأسود (E172)، شمع كارنوبا (E903).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; أقراص ستيقلوجان 5 ملغم /100 ملغم المُغلّفة هي أقراص لونها بيج، يبلغ حجمها 12.0 &times; &nbsp;7.4 مم، لوزيّة الشكل، منقوش على أحد جانبيها فقط الرقم &nbsp;&quot;554&quot; .</p><p dir="RTL">&bull; أقراص ستيقلوجان 15 ملغم /100 ملغم المُغلّفة هي أقراص لونها بُنّي، يبلغ حجمها 12.0 &times; 7.4 مم، لوزيّة الشكل، منقوش على أحد جانبيها فقط الرقم&nbsp; &quot;555&quot; .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر ستيقلوجان في شرائط من الألومنيوم مصنوعة من Alu / PVC / PA / Alu. تتضمن أحجام العبوات 14 و 28 و 30 و 84 و 90 و 98 قرص مُغلف بغشاء رقيق على شكل شرائط من الألومنيوم غير مُثَقبة وعبوات تحتوي على 30 &times; 1 قرص على شكل شريط من الألومنيوم المُثقّبة المُحددة الجرعة. &nbsp;</p><p dir="RTL"><strong>قد لا يتم تسويق جميع أحجام العبوات.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي. في.</p><p dir="RTL">واردرويج</p><p dir="RTL">٢٠٣١ بي ان هارلم</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة :</strong></p><p dir="RTL">شيرينغ - بلاو لابو إن في</p><p dir="RTL">إندستريبارك 30</p><p dir="RTL">هايست-أوب- دن- بيرغ، بي- ٢٢٢٠</p><p dir="RTL">&nbsp;بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            لقد تمت مراجعة هذه النشرة بتاريخ يوليو 2020

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية، الهيئة العامة للغذاء والدواء
فاكس: +966-11-205-7662
للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات . هاتف: +966-11-20382222	
تحويلة: 2317-2356-2353-2354-2334-2340
الهاتف المجاني: 8002490000  
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: www.sfda.gov.sa/npc
•	دول الخليج الأخرى
الرجاء الإتصال بالمؤسسات والهيئات الوطنية في كل دولة.

	
(إن هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Steglujan 5 mg/100 mg film-coated tablets 
Steglujan 15 mg/100 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Steglujan 5 mg/100 mg film-coated tablets
Each tablet contains 5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).

Steglujan 15 mg/100 mg film-coated tablets
Each tablet contains 15 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Steglujan 5 mg/100 mg film-coated tablets
Beige, 12.0 x 7.4 mm, almond-shaped, film-coated tablets debossed with “554” on one side and plain on the other side.

Steglujan 15 mg/100 mg film-coated tablets
Brown, 12.0 x 7.4 mm, almond-shaped, film-coated tablets debossed with “555” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.</p><p>&nbsp;</p><p>(For study results with respect to combinations and effects on glycaemic control, see sections 4.4, 4.5, and 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily. In patients tolerating the starting dose, the dose may be increased to 15 mg ertugliflozin/100 mg sitagliptin, once daily, if additional glycaemic control is needed.</p><p>&nbsp;</p><p>For patients treated with ertugliflozin who are being switched to Steglujan, the dose of ertugliflozin can be maintained.</p><p>&nbsp;</p><p>When Steglujan is used in combination with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycaemia (see sections 4.4, 4.5, and 4.8).</p><p>&nbsp;</p><p>In patients with volume depletion, correcting this condition prior to initiation of Steglujan is recommended (see section 4.4).</p><p>&nbsp;</p><p>If a dose is missed, it should be taken as soon as the patient remembers. Patients should not take two doses of Steglujan on the same day.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>Assessment of renal function is recommended prior to initiation of Steglujan and periodically thereafter (see section 4.4).</p><p>&nbsp;</p><p>Initiation of this medicinal product is not recommended in patients with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2&nbsp;or CrCl less than 60 ml/min (see section 4.4).</p><p>Steglujan should be discontinued when eGFR is persistently less than 45 ml/min/1.73 m2&nbsp;or CrCl is persistently less than 45 ml/min.</p><p>&nbsp;</p><p>The fixed-dose combination of ertugliflozin and sitagliptin should not be used in patients with severe renal impairment, with end-stage renal disease (ESRD), or receiving dialysis. Ertugliflozin is not expected to be effective in these patients.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Steglujan is necessary in patients with mild or moderate hepatic impairment. Steglujan has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly (&ge; 65 years old)</em></p><p>No dose adjustment of Steglujan is recommended based on age. Elderly patients are more likely to have decreased renal function. Because renal function abnormalities can occur after initiating ertugliflozin, and sitagliptin is known to be substantially excreted by the kidneys, renal function should be assessed more frequently in elderly patients. Renal function and risk of volume depletion should be taken into account (see sections 4.4 and 4.8). There is limited experience with Steglujan in patients &ge; 75 years of age.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Steglujan in children under 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Steglujan should be taken orally once daily in the morning, with or without food. In case of swallowing difficulties, the tablet could be broken or crushed as it is an immediate-release dosage form.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Steglujan should not be used in patients with type 1 diabetes mellitus.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p>Use of dipeptidyl peptidase-4 (DPP-4) inhibitors has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. Resolution of pancreatitis has been observed after discontinuation of sitagliptin (with or without supportive treatment), but very rare cases of necrotising or haemorrhagic pancreatitis and/or death have been reported. If pancreatitis is suspected, Steglujan and other potentially suspect medicinal products should be discontinued; if acute pancreatitis is confirmed, Steglujan should not be restarted. Caution should be exercised in patients with a history of pancreatitis.</p><p>&nbsp;</p><p><u>Hypotension/Volume depletion</u></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Steglujan (see section 4.8), particularly in patients with impaired renal function (eGFR less than 60 ml/min/1.73 m<sup>2</sup> or CrCl less than</p><p>60 ml/min), elderly patients (&ge; 65 years), patients on diuretics, or patients on anti-hypertensive therapy with a history of hypotension. Before initiating Steglujan, volume status should be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy.</p><p>&nbsp;</p><p>Due to its mechanism of action, ertugliflozin induces an osmotic diuresis and increases serum creatinine and decreases eGFR. Increases in serum creatinine and decreases in eGFR were greater in patients with moderate renal impairment (see section 4.8).</p><p>&nbsp;</p><p>In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving Steglujan. Temporary interruption of treatment with Steglujan should be considered until the fluid loss is corrected.</p><p>&nbsp;</p><p><u>Diabetic ketoacidosis</u></p><p>Rare cases of DKA, including life-threatening and fatal cases, have been reported in clinical trials and post-marketing in patients treated with sodium glucose co-transporter-2 (SGLT2) inhibitors, and cases have been reported in clinical trials with ertugliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/l</p><p>(250 mg/dl). It is not known if DKA is more likely to occur with higher doses of ertugliflozin.</p><p>&nbsp;</p><p>The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.</p><p>&nbsp;</p><p>In patients where DKA is suspected or diagnosed, treatment with Steglujan should be discontinued immediately.</p><p>&nbsp;</p><p>Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. Monitoring of ketones is recommended in these patients. Measurement of blood ketone levels is preferred to urine. Treatment with Steglujan may be restarted when the ketone values are normal and the patient&rsquo;s condition has stabilised.</p><p>&nbsp;</p><p>Before initiating Steglujan, factors in the patient history that may predispose to ketoacidosis should be considered.</p><p>&nbsp;</p><p>Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g., type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or</p><p>&nbsp;</p><p>patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery, or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.</p><p>&nbsp;</p><p>Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.</p><p>&nbsp;</p><p>The safety and efficacy of Steglujan in patients with type 1 diabetes have not been established and Steglujan should not be used for treatment of patients with type 1 diabetes. Limited data from clinical trials suggest that DKA occurs with common frequency when patients with type 1 diabetes are treated with SGLT2 inhibitors.</p><p>&nbsp;</p><p><u>Lower limb amputations</u></p><p>In an ongoing clinical study of ertugliflozin added to existing therapy in type 2 diabetes patients with a history of established cardiovascular disease, an approximately 1.2-1.6-fold increase in cases of lower limb amputation (primarily of the toe) has been observed in patients treated with ertugliflozin. An increase in cases of lower limb amputation (primarily of the toe) has also been observed in long-term clinical studies with another SGLT2 inhibitor. As an underlying mechanism has not been established, risk factors, apart from general risk factors, for amputation are unknown.</p><p>&nbsp;</p><p>Before initiating ertugliflozin/sitagliptin, consider factors in the patient history that may increase the risk for amputation. As precautionary measures, consideration should be given to carefully monitoring patients with a higher risk for amputation events and counselling patients about the importance of routine preventative foot care and maintaining adequate hydration. Consideration may also be given to stopping treatment with ertugliflozin/sitagliptin in patients who develop events which may precede amputation such as lower-extremity skin ulcer, infection, osteomyelitis or gangrene.</p><p>&nbsp;</p><p><u>Impairment in renal function</u></p><p>The efficacy of ertugliflozin is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Steglujan should not be initiated in patients with an eGFR below 60 ml/min/1.73 m<sup>2</sup> or CrCl below 60 ml/min. Steglujan should be discontinued when eGFR is persistently below 45 ml/min/1.73 m<sup>2</sup> or CrCl is persistently below 45 ml/min due to a reduction of efficacy.</p><p>&nbsp;</p><p>Monitoring of renal function is recommended as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to Steglujan initiation and periodically during treatment (see section 4.2).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; More frequently in patients with an eGFR below 60 ml/min/1.73 m<sup>2</sup> or a CrCl below 60 ml/min.</p><p>&nbsp;</p><p><u>Hypoglycaemia with concomitant use with insulin and insulin secretagogues</u></p><p>Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue, which are known to cause hypoglycaemia (see section 4.8). Hypoglycaemia has been observed when sitagliptin was used in combination with insulin or a sulphonylurea. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimise the risk of hypoglycaemia when used in combination with Steglujan (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p><u>Genital mycotic infections</u></p><p>Ertugliflozin increases the risk of genital mycotic infections. In trials with SGLT2 inhibitors, patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections (see section 4.8). Patients should be monitored and treated appropriately.</p><p>&nbsp;</p><p><u>Urinary tract infections</u></p><p>Urinary glucose excretion may be associated with an increased risk of urinary tract infections.</p><p>The incidence of urinary tract infections was not notably different in the ertugliflozin 5 mg and 15 mg groups (4.0% and 4.1%) and the placebo group (3.9%). Most of the events were mild or moderate and</p><p>&nbsp;</p><p>no serious case was reported. Temporary interruption of ertugliflozin should be considered when treating pyelonephritis or urosepsis.</p><p>&nbsp;</p><p><u>Necrotising fasciitis of the perineum (Fournier&rsquo;s gangrene)</u></p><p>Post-marketing cases of necrotising fasciitis of the perineum, (also known as Fournier&rsquo;s gangrene), have been reported in female and male patients taking SGLT2 inhibitors. This is a rare but serious and potentially life-threatening event that requires urgent surgical intervention and antibiotic treatment.</p><p>&nbsp;</p><p>Patients should be advised to seek medical attention if they experience a combination of symptoms of pain, tenderness, erythema, or swelling in the genital or perineal area, with fever or malaise. Be aware that either uro-genital infection or perineal abscess may precede necrotising fasciitis. If Fournier&rsquo;s gangrene is suspected, Steglujan should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>Post-marketing reports of serious hypersensitivity reactions in patients treated with sitagliptin have been reported (see section 4.8). These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first</p><p>3 months after initiation of treatment, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, Steglujan should be discontinued. Other potential causes for the event should be assessed, and alternative treatment for diabetes initiated.</p><p>&nbsp;</p><p><u>Bullous pemphigoid</u></p><p>There have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including sitagliptin. If bullous pemphigoid is suspected, Steglujan should be discontinued.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Elderly patients may be at an increased risk of volume depletion. Patients 65 years and older treated with ertugliflozin, had a higher incidence of adverse reactions related to volume depletion compared to younger patients. Steglujan is expected to have diminished efficacy in elderly patients with renal impairment (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with Steglujan in NYHA class III-IV.</p><p>&nbsp;</p><p><u>Urine laboratory assessments</u></p><p>Due to the mechanism of action of ertugliflozin, patients taking Steglujan will test positive for glucose in their urine. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Interference with 1,5-anhydroglucitol (1,5-AG) assay</u></p><p>Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic drug interaction studies with Steglujan have not been performed; however, such studies have been conducted with ertugliflozin and sitagliptin, the individual active substances of Steglujan.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><em><u>Pharmacodynamic interactions</u></em></p><p><em>&nbsp;</em></p><p><em>Diuretics</em></p><p>Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension (see section 4.4).</p><p>&nbsp;</p><p><em>Insulin and insulin secretagogues</em></p><p>Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with Steglujan (see sections 4.2, 4.4, and 4.8).</p><p>&nbsp;</p><p><em><u>Pharmacokinetic interactions</u></em></p><p><em>&nbsp;</em></p><p><em><u>Effects of other medicinal products</u></em><em><u> on the pharmacokinetics of ertugliflozin</u></em></p><p>Metabolism by UGT1A9 and UGT2B7 is the primary clearance mechanism for ertugliflozin.</p><p>&nbsp;</p><p>Interaction studies conducted in healthy subjects, using a single dose design, suggest that the pharmacokinetics of ertugliflozin are not altered by sitagliptin, metformin, glimepiride, or simvastatin.</p><p>&nbsp;</p><p>Multiple-dose administration of rifampin (a UGT and CYP inducer) decreases ertugliflozin AUC and Cmax&nbsp;by 39% and 15%, respectively. This decrease in exposure is not considered clinically relevant and therefore, no dose adjustment is recommended. A clinically relevant effect with other inducers (e.g., carbamazepine, phenytoin, phenobarbital) is not expected.</p><p>&nbsp;</p><p>The impact of UGT inhibitors on the pharmacokinetics of ertugliflozin has not been studied clinically, but potential increase in ertugliflozin exposure due to UGT inhibition is not considered to be clinically relevant.</p><p>&nbsp;</p><p><em><u>Effects of ertugliflozin on the pharmacokinetics of other medicinal products</u></em></p><p>Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride.</p><p>&nbsp;</p><p>Coadministration of simvastatin with ertugliflozin resulted in a 24% and 19% increase in AUC and Cmax&nbsp;of simvastatin, respectively, and 30% and 16% increase in AUC and Cmax&nbsp;of simvastatin acid, respectively. The mechanism for the small increases in simvastatin and simvastatin acid is unknown and is not perpetrated through OATP inhibition by ertugliflozin. These increases are not considered to be clinically meaningful.</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p><em><u>Pharmacokinetic interactions</u></em></p><p><em>&nbsp;</em></p><p><em><u>Effects of other medicinal products on sitagliptin</u></em></p><p>Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway. <em>In vitro </em>studies indicate that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.</p><p>&nbsp;</p><p>Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD). For this reason, it is possible that potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the pharmacokinetics of sitagliptin in patients with severe renal impairment or ESRD.</p><p>Interaction studies conducted in patients with type 2 diabetes or healthy volunteers suggest that metformin and ciclosporin had no clinically relevant effect on the pharmacokinetics of sitagliptin.</p><p>&nbsp;</p><p><em><u>Effects of sitagliptin on other medicinal products</u></em></p><p>In drug interaction studies, sitagliptin did not have clinically meaningful effects on the pharmacokinetics of the following: metformin, rosiglitazone, glyburide, simvastatin, warfarin, and oral contraceptives.</p><p>&nbsp;</p><p><em>Digoxin: </em>Sitagliptin had a small effect on plasma digoxin concentrations. Following administration of</p><p>0.25 mg digoxin concomitantly with 100 mg of sitagliptin daily for 10 days, the plasma AUC of digoxin was increased on average by 11% and the plasma Cmax on average by 18%. No dose adjustment of digoxin is recommended. However, patients at risk of digoxin toxicity should be monitored for this when sitagliptin and digoxin are administered concomitantly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Steglujan in pregnant women. There are limited data from the use of ertugliflozin in pregnant women. Based on results from animal studies, ertugliflozin may affect renal development and maturation (see section 5.3). Therefore, Steglujan should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no information regarding the presence of Steglujan or its individual components in human milk, the effects on the breast-fed infant, or the effects on milk production. No studies in lactating animals have been conducted with the combined components of Steglujan. Ertugliflozin and sitagliptin are present in the milk of lactating rats. Ertugliflozin caused effects in the offspring of lactating rats.</p><p>&nbsp;</p><p>Pharmacologically mediated effects were observed in juvenile rats treated with ertugliflozin (see section 5.3). Since human kidney maturation occurs <em>in utero </em>and during the first 2 years of life when</p><p>&nbsp;</p><p>exposure from breast-feeding may occur, a risk to newborns/infants cannot be excluded. Steglujan should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effect of Steglujan on fertility in humans has not been studied. No effects of ertugliflozin or sitagliptin on fertility were observed in animal studies (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Steglujan has no or negligible influence on the ability to drive and use machines. However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported with sitagliptin. In addition, patients should be alerted to the risk of hypoglycaemia when Steglujan is used in combination with insulin or an insulin secretagogue and to the elevated risk of adverse reactions related to volume depletion, such as postural dizziness (see sections 4.2, 4.4, and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><em><u>Ertugliflozin and Sitagliptin</u></em></p><p>The safety of concomitantly administered ertugliflozin and sitagliptin has been evaluated in</p><p>990 patients with type 2 diabetes mellitus treated for 26 weeks in three studies; a factorial study of ertugliflozin 5 mg or 15 mg in combination with sitagliptin 100 mg once daily compared to the individual components, a placebo-controlled study of ertugliflozin 5 mg or 15 mg as add-on therapy to sitagliptin 100 mg and metformin once daily, and a placebo-controlled study of initial therapy with ertugliflozin 5 mg or 15 mg once daily in combination with sitagliptin 100 mg once daily (see</p><p>section 5.1). The incidence and type of adverse reactions in these three studies were similar to the adverse reactions seen with ertugliflozin and are described below in Table 1. There were no additional adverse reactions identified in these three trials that included sitagliptin relative to the three placebo- controlled studies with ertugliflozin (see below).</p><p>&nbsp;</p><p><em><u>Ertugliflozin</u></em></p><p><em>&nbsp;</em></p><p><em>Pool</em><em> of placebo-controlled trials</em></p><p>The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials.</p><p>Ertugliflozin was used as monotherapy in one trial and as add-on therapy in two trials (see section 5.1). These data reflect exposure of 1,029 patients to ertugliflozin with a mean exposure</p><p>duration of approximately 25 weeks. Patients received ertugliflozin 5 mg (N=519), ertugliflozin 15 mg (N=510), or placebo (N=515) once daily.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions across the clinical program were vulvovaginal mycotic infection and other female genital mycotic infections. Serious diabetic ketoacidosis occurred rarely.</p><p>See &ldquo;Description of selected adverse reactions&rdquo; for frequencies and see section 4.4.</p><p>&nbsp;</p><p><em><u>Sitagliptin</u></em></p><p>Serious adverse reactions including pancreatitis and hypersensitivity reactions have been reported. Hypoglycaemia has been reported in combination with sulphonylurea (4.7%-13.8%) and insulin (9.6%) (see section 4.4).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions listed below are classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 1: Adverse reactions</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p><p>Frequency</p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Common</p></td><td style="vertical-align:top"><p>Vulvovaginal mycotic infection and other female genital mycotic infections*,&dagger;,1</p><p><strong>&nbsp;</strong></p><p>Balanitis candida and other male genital mycotic infections*,&dagger;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including anaphylactic responses*,a,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common Rare</p></td><td style="vertical-align:top"><p>Hypoglycaemia*,&dagger;,1,2</p><p><strong>&nbsp;</strong></p><p>Diabetic ketoacidosis*,&dagger;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common Uncommon</p></td><td style="vertical-align:top"><p>Headache2&nbsp;Dizziness2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Interstitial lung diseasea,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Constipation2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomitinga,2</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Not known</p><p>Not known</p></td><td style="vertical-align:top"><p>Acute pancreatitisa,*,b,2</p><p>Fatal and non-fatal haemorrhagic and necrotizing</p></td></tr><tr><td style="vertical-align:top"><p>pancreatitis*,a,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pruritusa,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedemaa,*,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p><p>Not known Not known</p></td><td style="vertical-align:top"><p>Rasha,*,2 Urticariaa,*,2</p><p>Cutaneous vasculitisa,*,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Exfoliative skin conditions including Stevens-Johnson syndromea,*,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Bullous pemphigoida, * ,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Arthralgiaa,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgiaa,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Back paina,2</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Arthropathya,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Volume depletion*,&dagger;,1</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>Common Uncommon</p><p><strong>&nbsp;</strong></p><p>Not known</p><p>Not known</p><p>Not known</p></td><td><p>Increased urination<sup>&Dagger;,1</sup></p><p>Dysuria<sup>1</sup>, Blood creatinine increased/Glomerular filtration rate decreased<sup>&dagger;,1</sup></p><p>Impaired renal function<sup>a,2</sup></p><p>Acute renal failure<sup>a,2</sup></p><p>Tubulointerstitial nephritis<sup>a,2</sup></p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vulvovaginal pruritus1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thirst&sect;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Serum lipids changed&para;,1, Haemoglobin increased **1, BUN increased&para;&para;1</p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp; &nbsp;Adverse reaction with ertugliflozin.</p><p>2&nbsp;&nbsp;&nbsp; &nbsp;Adverse reaction with sitagliptin.</p><p>* &nbsp;See Section 4.4.</p><p>&dagger;&nbsp;&nbsp;&nbsp; &nbsp;See subsections below for additional information.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; &nbsp;Includes: pollakiuria, micturition urgency, polyuria, urine output increased, and nocturia.</p><p>&sect;&nbsp;&nbsp;&nbsp; &nbsp;Includes: thirst and polydipsia.</p><p>&para;&nbsp;&nbsp;&nbsp; &nbsp;Mean percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were LDL-C 5.8%</p><p>and 8.4% versus 3.2%; total cholesterol 2.8% and 5.7% versus 1.1%; however, HDL-C 6.2% and 7.6% versus 1.9%. Median percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were triglycerides -3.9% and -1.7% versus 4.5%.</p><p>**&nbsp; &nbsp;The proportion of subjects having at least 1 increase in haemoglobin &gt; 2.0 g/dL was higher in the ertugliflozin 5 mg and 15 mg groups (4.7% and 4.1%, respectively) compared to the placebo group (0.6%).</p><p>&para;&para;&nbsp; &nbsp;The proportion of subjects having any occurrence of BUN values &ge;50% increase and value &gt;ULN was numerically</p><p>higher in the ertugliflozin 5 mg group and higher in the 15 mg group (7.9% and 9.8%, respectively) relative to the placebo group (5.1%).</p><p>a&nbsp;&nbsp;&nbsp; &nbsp;Adverse reactions were identified through post-marketing surveillance.</p><p>b&nbsp;&nbsp;&nbsp; &nbsp;See <em>TECOS Cardiovascular Safety Study </em>below.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Volume depletion (ertugliflozin)</u></em></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion. In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension and orthostatic hypotension) was low (&lt; 2%) and not notably different across the ertugliflozin and placebo groups. In the subgroup analyses in the broader pool of Phase 3 studies, subjects with eGFR &lt; 60 mL/min/1.73 m2, subjects &ge; 65 years of age and subjects on diuretics had a higher incidence of volume depletion in the ertugliflozin groups relative to the comparator group (see sections 4.2 and 4.4). In subjects with eGFR &lt; 60 mL/min/1.73 m2, the incidence was 5.1%, 2.6% and 0.5% for ertugliflozin 5 mg, ertugliflozin 15 mg and the comparator group and for subjects with eGFR 45 to &lt; 60 mL/min/1.73 m2, the incidence was 6.4%, 3.7% and 0% respectively.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em><em><u> (ertugliflozin)</u></em></p><p>In the pool of placebo-controlled studies, the incidence of documented hypoglycemia was increased for ertugliflozin 5 mg and 15 mg (5.0% and 4.5%) compared to placebo (2.9%). In this population, the incidence of severe hypoglycaemia was 0.4% in each group. When ertugliflozin was used as monotherapy, the incidence of hypoglycaemic events in the ertugliflozin groups was 2.6% in both groups and 0.7% in the placebo group. When used as add-on to metformin, the incidence of hypoglycaemic events was 7.2% in the ertugliflozin 5 mg group, 7.8% in the ertugliflozin 15 mg</p><p>group and 4.3% in the placebo group.</p><p>&nbsp;</p><p>When ertugliflozin was added to metformin and compared to sulphonylurea, the incidence of hypoglycaemia was higher for the sulphonylurea (27%) compared to ertugliflozin (5.6% and 8.2% for ertugliflozin 5 mg and 15 mg, respectively).</p><p>&nbsp;</p><p>In patients with moderate renal impairment taking insulins, SU, or meglitinides as background medication, documented hypoglycaemia was 36%, 27% and 36% for ertugliflozin 5 mg, ertugliflozin</p><p>15 mg, and placebo, respectively (see sections 4.2, 4.4, and 4.5).</p><p>&nbsp;</p><p><em><u>Diabetic Ketoacidosis (ertugliflozin)</u></em></p><p>Across the clinical program for ertugliflozin, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4).</p><p>&nbsp;</p><p><em><u>Blood creatinine increased/Glomerular filtration rate decreased and renal-related events</u></em><em> </em><em><u>(ertugliflozin)</u></em></p><p>Initial increases in mean creatinine and decreases in mean eGFR in patients treated with ertugliflozin were generally transient during continuous treatment. Patients with moderate renal impairment at baseline had larger mean changes that did not return to baseline at Week 26; these changes reversed after treatment discontinuation.</p><p>&nbsp;</p><p>Renal-related adverse reactions (e.g., acute kidney injury, renal impairment, acute prerenal failure) may occur in patients treated with ertugliflozin, particularly in patients with moderate renal impairment where the incidence of renal-related adverse reactions was 2.5%, 1.3%, and 0.6% in patients treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively.</p><p>&nbsp;</p><p><em><u>Genital mycotic infections (ertugliflozin)</u></em></p><p>In the pool of three placebo-controlled clinical trials, female genital mycotic infections (e.g., genital candidiasis, genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginitis) occurred in 9.1%, 12%, and 3.0% of females treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. In females, discontinuation due to genital mycotic infections occurred in 0.6% and 0% of patients treated with ertugliflozin and placebo, respectively (see section 4.4).</p><p>&nbsp;</p><p>In the same pool, male genital mycotic infections (e.g., balanitis candida, balanoposthitis, genital infection, genital infection fungal) occurred in 3.7%, 4.2%, and 0.4% of males treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. Male genital mycotic infections occurred more commonly in uncircumcised males. In males, discontinuations due to genital mycotic infections occurred in 0.2% and 0% of patients treated with ertugliflozin and placebo, respectively. In rare instances, phimosis was reported and sometimes circumcision was performed (see section 4.4).</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p>In addition to the adverse reactions described in the table above, adverse experiences reported regardless of causal relationship to medication and occurring in at least 5% and more commonly in patients treated with sitagliptin included upper respiratory tract infection and nasopharyngitis.</p><p>Additional adverse experiences reported regardless of causal relationship to medication that occurred more frequently in patients treated with sitagliptin (not reaching the 5% level, but occurring with an incidence of &gt; 0.5% higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity.</p><p>&nbsp;</p><p>Some adverse reactions were observed more frequently in studies of combination use of sitagliptin with other anti-diabetic medicinal products than in studies of sitagliptin monotherapy. These included hypoglycaemia (frequency very common with the combination of sulphonylurea and metformin), influenza (common with insulin (with or without metformin)), nausea and vomiting (common with metformin), flatulence (common with metformin or pioglitazone), constipation (common with the combination of sulphonylurea and metformin), peripheral oedema (common with pioglitazone or the combination of pioglitazone and metformin), somnolence and diarrhoea (uncommon with metformin), and dry mouth (uncommon with insulin (with or without metformin)).</p><p>&nbsp;</p><p><em>TECOS</em><em> (trial evaluating cardiovascular outcomes with sitagliptin)</em></p><p>The cardiovascular safety study with sitagliptin (TECOS) included 7,332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was &ge; 30 and &lt; 50 ml/min/1.73 m2), and</p><p>&nbsp;</p><p>7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care targeting regional standards for HbA1c and CV risk factors. The overall incidence of</p><p>serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.</p><p>&nbsp;</p><p>In the intention-to-treat population, among patients who were using insulin and/or a sulphonylurea at baseline, the incidence of severe hypoglycaemia was 2.7% in sitagliptin-treated patients and 2.5% in placebo-treated patients; among patients who were not using insulin and/or a sulphonylurea at baseline, the incidence of severe hypoglycaemia was 1.0% in sitagliptin-treated patients and 0.7% in placebo-treated patients. The incidence of adjudication-confirmed pancreatitis events was 0.3% in sitagliptin-treated patients and 0.2% in placebo-treated patients.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of an overdose with Steglujan, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring including obtaining an electrocardiogram, and institute supportive treatment) as dictated by the patient&rsquo;s clinical status.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>Ertugliflozin did not show any toxicity in healthy subjects at single oral doses up to 300 mg and multiple doses up to 100 mg daily for 2 weeks. No potential acute symptoms and signs of overdose were identified. Removal of ertugliflozin by haemodialysis has not been studied.</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p>During controlled clinical trials in healthy subjects, single doses of up to 800 mg sitagliptin were administered. Minimal increases in QTc, not considered to be clinically relevant, were observed in one study at a dose of 800 mg sitagliptin. There is no experience with doses above 800 mg in clinical studies. In Phase 1 multiple-dose studies, there were no dose-related clinical adverse reactions observed with sitagliptin with doses of up to 600 mg per day for periods of up to 10 days and 400 mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per day for periods of up to 28 days.</p><p>&nbsp;</p><p>Sitagliptin is modestly dialysable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour haemodialysis session. Prolonged haemodialysis may be considered if clinically appropriate. It is not known if sitagliptin is dialysable by peritoneal dialysis.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD24.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Steglujan combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is a potent, selective, and reversible inhibitor of SGLT2.</p><p>&nbsp;</p><p>By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p>Sitagliptin is a member of a class of oral antihyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones. Incretin hormones, including</p><p>glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signalling pathways involving cyclic AMP. Treatment with GLP-1 or with DPP-4 inhibitors in animal models of type 2 diabetes has been demonstrated to improve beta cell responsiveness to glucose and stimulate insulin biosynthesis and release. With higher insulin levels, tissue glucose uptake is enhanced. In addition, GLP-1 lowers glucagon secretion from pancreatic alpha cells. Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels. The effects of GLP-1 and GIP are glucose-dependent such that when blood glucose concentrations are low, stimulation of insulin release and suppression of glucagon secretion by GLP-1 are not observed. For both GLP-1 and GIP, stimulation of insulin release is enhanced as glucose rises above normal concentrations. Further, GLP-1 does not impair the normal glucagon response to hypoglycaemia. The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyses the incretin hormones to produce inactive products. Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 and GIP. By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose-dependent manner. In patients with type 2 diabetes with hyperglycaemia, these changes in insulin and glucagon levels lead to lower haemoglobin A1c&nbsp;(HbA1c) and lower fasting and post-prandial glucose concentrations. The glucose-dependent mechanism of sitagliptin is distinct from the mechanism of sulphonylureas, which increase insulin secretion even when glucose levels are low and can lead to hypoglycaemia in patients with type 2 diabetes and in normal subjects. Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.</p><p>&nbsp;</p><p>In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents.</p><p>Coadministration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. Sitagliptin, but not metformin, increased active GIP concentrations.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><em>Urinary glucose excretion and urinary volume</em></p><p>Dose-dependent increases in the amount of glucose excreted in urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following single- and multiple-dose administration of ertugliflozin. Dose-response modelling indicates that ertugliflozin 5 mg and 15 mg result in near maximal urinary glucose excretion (UGE) in patients with type 2 diabetes mellitus, providing 87% and 96% of maximal inhibition, respectively.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Ertugliflozin in combination with sitagliptin</em></p><p>The efficacy and safety of ertugliflozin in combination with sitagliptin have been studied in 3 multi- centre, randomised, double-blind, placebo- and active comparator-controlled, Phase 3 clinical studies involving 1,985 patients with type 2 diabetes. Across the 3 studies, the racial distribution ranged from 72.9% to 90.4% White, 0.0% to 20.3% Asian, 1.9% to 4.5% Black and 4.8% to 5.4% Other. Hispanic or Latino patients comprised 15.6% to 36.1% of the population. The mean age of the patients across</p><p>&nbsp;</p><p>these 3 studies ranged from 55.1 to 59.1 years (range 21 years to 85 years). Across the 3 studies, 16.2% to 29.9% of patients were &ge; 65 years of age and 2.3% to 2.8% were &ge; 75 years of age.</p><p>&nbsp;</p><p><em>Factorial study with ertugliflozin and sitagliptin as add-on combination therapy with </em><em>metformin</em></p><p>A total of 1,233 patients with type 2 diabetes participated in a randomised, double-blind, multi-centre, 26-week, active-controlled study to evaluate the efficacy and safety of ertugliflozin 5 mg or 15 mg in combination with sitagliptin 100 mg compared to the individual components. Patients with type 2 diabetes inadequately controlled on metformin monotherapy (&ge; 1,500 mg/day) were randomised to one of five active-treatment arms: ertugliflozin 5 mg or 15 mg, sitagliptin 100 mg, or sitagliptin 100 mg in combination with 5 mg or 15 mg ertugliflozin administered once daily in addition to continuation of background metformin therapy (see Table 2).</p><p>&nbsp;</p><p>Table 2: Results at Week 26 from a factorial study with ertugliflozin and sitagliptin as add-on combination therapy with metformin compared to individual components alone*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg + Sitagliptin 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin 15</strong><strong> </strong><strong>mg</strong></p><p><strong>+ Sitagliptin 100 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline (LS mean&dagger;) Difference from</p><p>Sitagliptin</p><p>Ertugliflozin 5 mg</p><p>Ertugliflozin 15 mg (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p><p>8.6</p><p>-1.0</p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p><p>8.6</p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p><p>8.5</p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p><p>8.6</p><p>-1.5</p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p><p>-0.5&Dagger; (-0.6, -0.3)</p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p><p>8.6</p><p>-1.5</p><p><strong>&nbsp;</strong></p><p>-0.5&Dagger; (-0.6, -0.3)</p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>66 (26.4)</p></td><td style="vertical-align:top"><p>79 (31.9)</p></td><td style="vertical-align:top"><p>81 (32.8)</p></td><td style="vertical-align:top"><p>127 &sect; (52.3)</p></td><td style="vertical-align:top"><p>120 &sect; (49.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>88.6</p></td><td style="vertical-align:top"><p>88.0</p></td><td style="vertical-align:top"><p>89.8</p></td><td style="vertical-align:top"><p>89.5</p></td><td style="vertical-align:top"><p>87.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td rowspan="3" style="vertical-align:top"><p>-2.7</p></td><td rowspan="3" style="vertical-align:top"><p>-3.7</p></td><td rowspan="3" style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-2.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from Sitagliptin</p></td><td rowspan="2" style="vertical-align:top"><p>-1.8&Dagger; (-2.5, -1.2)</p></td><td rowspan="2" style="vertical-align:top"><p>-2.3&Dagger; (-2.9, -1.6)</p></td></tr><tr><td style="vertical-align:top"><p>(LS mean&dagger;, 95% CI)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, baseline eGFR and the interaction of time by treatment.</p><p>&Dagger;&nbsp; &nbsp;p&lt; 0.001 compared to control group.</p><p>&sect;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to corresponding dose of ertugliflozin or sitagliptin (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Ertugliflozin as add-on combination therapy with metformin and </em><em>sitagliptin</em></p><p>A total of 463 patients, with type 2 diabetes inadequately controlled on metformin (&ge; 1,500 mg/day) and sitagliptin 100 mg once daily participated in a randomised, double-blind, multi-centre, 26-week, placebo-controlled study to evaluate the efficacy and safety of ertugliflozin. Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin and sitagliptin therapy (see Table 3).</p><p>&nbsp;</p><p>Table 3: Results at Week 26 from an add-on study of ertugliflozin in combination with metformin and sitagliptin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin 15</strong><strong> </strong><strong>mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>8.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>-0.9</p></td><td rowspan="2" style="vertical-align:top"><p>-0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-0.7&Dagger; (-0.9, -0.5)</p></td><td style="vertical-align:top"><p>-0.8&Dagger; (-0.9, -0.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt;7%</strong></p></td><td style="vertical-align:top"><p>50 (32.1)&sect;</p></td><td style="vertical-align:top"><p>61 (39.9)&sect;</p></td><td style="vertical-align:top"><p>26 (17.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.6</p></td><td style="vertical-align:top"><p>86.6</p></td><td style="vertical-align:top"><p>86.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.3</p></td><td style="vertical-align:top"><p>-3.0</p></td><td rowspan="2" style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-2.0&Dagger; (-2.6, -1.4)</p></td><td style="vertical-align:top"><p>-1.7&Dagger; (-2.3, -1.1)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, prior antihyperglycaemic medication, baseline eGFR, and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Combination therapy of ertugliflozin and sitagliptin</em></p><p>A total of 291 patients with type 2 diabetes inadequately controlled on diet and exercise participated in a randomised, double-blind, multi-centre, placebo-controlled 26-week study to evaluate the efficacy and safety of ertugliflozin in combination with sitagliptin. These patients, who were not receiving any background antihyperglycaemic treatment, were randomised to ertugliflozin 5 mg or ertugliflozin</p><p>15 mg in combination with sitagliptin (100 mg) or to placebo, once daily (see Table 4).</p><p>&nbsp;</p><p>Table 4: Results at Week-26 from a combination therapy study of ertugliflozin and sitagliptin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>5 mg</strong></p><p><strong>+ Sitagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>15 mg</strong></p><p><strong>+ Sitagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 98</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>9.0</p></td><td style="vertical-align:top"><p>9.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-1.6</p></td><td style="vertical-align:top"><p>-1.7</p></td><td rowspan="3" style="vertical-align:top"><p>-0.4</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger; and 95%</p></td><td rowspan="2" style="vertical-align:top"><p>-1.2&Dagger; (-1.5, -0.8)</p></td><td rowspan="2" style="vertical-align:top"><p>-1.2&Dagger; (-1.6, -0.9)</p></td></tr><tr><td style="vertical-align:top"><p>CI)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [n (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>35&sect; (35.7)</p></td><td style="vertical-align:top"><p>30&sect; (31.3)</p></td><td style="vertical-align:top"><p>8 (8.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 98</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td><td style="vertical-align:top"><p><strong>N = 97</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>90.8</p></td><td style="vertical-align:top"><p>91.3</p></td><td style="vertical-align:top"><p>95.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-2.9</p></td><td style="vertical-align:top"><p>-3.0</p></td><td rowspan="2" style="vertical-align:top"><p>-0.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-2.0&Dagger; (-3.0, -1.0)</p></td><td style="vertical-align:top"><p>-2.1&Dagger; (-3.1, -1.1)</p></td></tr></tbody></table><p>* N includes all patients who received at least one dose of study medication and had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp; &nbsp;Least squares means adjusted for treatment, time, antihyperglycemic medication wash-off status, baseline eGFR, and the interaction of time by treatment.</p><p>&Dagger;&nbsp; &nbsp;p&lt; 0.001 compared to placebo.</p><p>&sect;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Fasting plasma glucose</em></p><p>In three placebo-controlled studies, ertugliflozin resulted in statistically significant reductions in FPG. For ertugliflozin 5 mg and 15 mg, respectively, the placebo-corrected reductions in FPG were 1.92 and</p><p>2.44 mmol/l as monotherapy, 1.48 and 2.12 mmol/l as add-on to metformin, and 1.40 and 1.74 mmol/l as add-on to metformin and sitagliptin.</p><p>&nbsp;</p><p>The combination of ertugliflozin and sitagliptin resulted in significantly greater reductions in FPG compared to sitagliptin or ertugliflozin alone or placebo. The combination of ertugliflozin 5 or 15 mg and sitagliptin resulted in incremental FPG reductions of 0.46 to 0.65 mmol/l compared to the ertugliflozin alone or 1.02 to 1.28 mmol/l compared to sitagliptin alone. The placebo-corrected reductions of ertugliflozin 5 or 15 mg in combination with sitagliptin were 2.16 and 2.56 mmol/l.</p><p>&nbsp;</p><p><em>Efficacy in patients with baseline HbA1c</em><em> </em><em>&ge; 10%</em></p><p>In the study of patients inadequately controlled on metformin with baseline HbA1c from 7.5-11.0%, among the subgroup of patients with a baseline HbA1c &ge; 10%, the combination of ertugliflozin 5 mg &nbsp;or 15 mg with sitagliptin resulted in reductions of HbA1c of 2.35% and 2.66%, respectively, compared to 2.10%, 1.30%, and 1.82% for ertugliflozin 5 mg, ertugliflozin 15 mg, and sitagliptin alone, respectively.</p><p>&nbsp;</p><p><em>Post-prandial glucose</em></p><p>When used in monotherapy, ertugliflozin 5 and 15 mg resulted in statistically significant placebo- corrected reductions in 2-hour post-prandial glucose (PPG) of 3.83 and 3.74 mmol/l.</p><p>&nbsp;</p><p>The combination of ertugliflozin 5 or 15 mg with sitagliptin resulted in statistically significant placebo-corrected reductions in 2-hour PPG of 3.46 and 3.87 mmol/l.</p><p>&nbsp;</p><p><em>Blood pressure</em></p><p>After 26-weeks of treatment, the combination of ertugliflozin 5 mg or 15 mg and sitagliptin 100 mg resulted in statistically significant reductions in systolic blood pressure (SBP) compared to sitagliptin alone (-2.8 and -3.0 mmHg for E5/S100 and E15/S100 respectively) or placebo (-4.4 and -6.4 mmHg for E5/S100 and E15/S100, respectively). Additionally, when added on to background metformin and sitagliptin therapy, ertugliflozin 5 mg and 15 mg resulted in statistically significant placebo subtracted reductions in SBP of 2.9 and 3.9 mmHg, respectively.</p><p>&nbsp;</p><p><em>Subgroup analysis</em></p><p>In patients with type 2 diabetes treated with ertugliflozin in combination with sitagliptin, the improvement in HbA1c was similar across subgroups defined by age, sex, and race, and duration of type 2 diabetes mellitus.</p><p>&nbsp;</p><p><em>TECOS Cardiovascular Safety Study</em></p><p>The TECOS was a randomised study in 14,671 patients in the intention-to-treat population with an HbA1c&nbsp;of &ge; 6.5 to 8.0% with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was &ge; 30 and &lt; 50 ml/min/1.73 m2) or placebo (7,339) added to</p><p>usual care targeting regional standards for HbA1c and CV risk factors. Patients with an eGFR</p><p>&lt; 30 ml/min/1.73 m2&nbsp;were not to be enrolled in the study. The study population included 2,004 patients &ge; 75 years of age and 3,324 patients with renal impairment</p><p>(eGFR &lt; 60 ml/min/1.73 m2).</p><p>&nbsp;</p><p>Over the course of the study, the overall estimated mean (SD) difference in HbA1c between the sitagliptin and placebo groups was 0.29% (0.01), 95% CI (-0.32, -0.27); p&lt; 0.001. The primary cardiovascular endpoint was a composite of the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Secondary cardiovascular endpoints included the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; first occurrence of the individual components of the primary composite; all-cause mortality; and hospital admissions for congestive heart failure.</p><p>&nbsp;</p><p>After a median follow up of 3 years, sitagliptin, when added to usual care, did not increase the risk of major adverse cardiovascular events or the risk of hospitalisation for heart failure compared to usual care without sitagliptin in patients with type 2 diabetes (see Table 5).</p><p>&nbsp;</p><p>Table 5: Rates of composite cardiovascular outcomes and key secondary outcomes</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Sitagliptin 100 mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hazard Ratio</strong><strong> </strong><strong>(95% CI)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>p-value</strong>&dagger;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Incidenc</strong><strong> </strong><strong>e rate per 100 patient- years</strong>*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Incidence</strong><strong> </strong><strong>rate per</strong><strong> </strong><strong>100</strong></p><p><strong>patient-</strong><strong> </strong><strong>years</strong>*</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Analysis in the Intention-to-Treat Population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>7,332</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>7,339</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>0.98 (0.89&ndash;1.08)</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Primary Composite Endpoint</strong><strong> </strong>(Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for unstable angina)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>839 (11.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4.1</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>851 (11.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Secondary Composite Endpoint</strong><strong> </strong>(Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>745 (10.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>3.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>746 (10.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>3.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>0.99 (0.89&ndash;1.10)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&lt;0.001</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Secondary Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>380 (5.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>366 (5.0)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.03 (0.89-1.19)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.711</p></td></tr><tr><td style="vertical-align:top"><p>All myocardial infarction (fatal and nonfatal)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>300 (4.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.4</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>316 (4.3)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.95 (0.81&ndash;1.11)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.487</p></td></tr><tr><td style="vertical-align:top"><p>All stroke (fatal and nonfatal)</p></td><td style="vertical-align:top"><p>178 (2.4)</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>183 (2.5)</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.97 (0.79&ndash;1.19)</p></td><td style="vertical-align:top"><p>0.760</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalisation for unstable angina</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>116 (1.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>129 (1.8)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.90 (0.70&ndash;1.16)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.419</p></td></tr><tr><td style="vertical-align:top"><p>Death from any cause</p></td><td style="vertical-align:top"><p>547 (7.5)</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>537 (7.3)</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>1.01 (0.90&ndash;1.14)</p></td><td style="vertical-align:top"><p>0.875</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for heart failure&Dagger;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>228 (3.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.1</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>229 (3.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.1</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.00 (0.83&ndash;1.20)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0.983</p></td></tr></tbody></table><p>*Incidence rate per 100 patient-years is calculated as 100 &times; (total number of patients with &ge; 1 event during eligible exposure period per total patient-years of follow-up).</p><p>&dagger; Based on a Cox model stratified by region. For composite endpoints, the p-values correspond to a test of non-inferiority seeking to show that the hazard ratio is less than 1.3. For all other endpoints, the p-values correspond to a test of differences</p><p>in hazard rates.</p><p>&Dagger;The analysis of hospitalisation for heart failure was adjusted for a history of heart failure at baseline.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Steglujan in all subsets of the paediatric population in the treatment of type 2 diabetes (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Steglujan</u></p><p>Steglujan has been shown to be bioequivalent to coadministration of corresponding doses of ertugliflozin and sitagliptin tablets.</p><p>&nbsp;</p><p>The effects of a high-fat meal on the pharmacokinetics of ertugliflozin and sitagliptin when administered as Steglujan tablets are comparable to those reported for the individual tablets. Administration of Steglujan with food decreased ertugliflozin Cmax&nbsp;by 29% and had no meaningful effect on ertugliflozin AUCinf, or on sitagliptin AUCinf&nbsp;and Cmax.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><em><u>General introduction</u></em></p><p>The pharmacokinetics of ertugliflozin are similar in healthy subjects and patients with type 2 diabetes. The steady state mean plasma AUC and Cmax&nbsp;were 398 ng∙hr/ml and 81 ng/ml, respectively, with 5 mg ertugliflozin once daily treatment, and 1,193 ng∙hr/ml and 268 ng/ml, respectively, with 15 mg ertugliflozin once daily treatment. Steady-state is reached after 4 to 6 days of once-daily dosing with ertugliflozin. Ertugliflozin does not exhibit time-dependent pharmacokinetics and accumulates in plasma up to 10-40% following multiple dosing.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour post-dose under fasted conditions. Plasma Cmax&nbsp;and AUC of ertugliflozin increase in a dose-proportional manner following single doses from 0.5 mg to 300 mg and following multiple doses from 1 mg to 100 mg. The absolute oral bioavailability of ertugliflozin following administration of a 15-mg dose is approximately 100%.</p><p>&nbsp;</p><p>Administration of ertugliflozin with a high-fat and high-calorie meal decreases ertugliflozin Cmax&nbsp;by 29% and prolongs Tmax&nbsp;by 1 hour, but does not alter AUC as compared with the fasted state. The observed effect of food on ertugliflozin pharmacokinetics is not considered clinically relevant, and ertugliflozin may be administered with or without food. In Phase 3 clinical trials, ertugliflozin was administered without regard to meals.</p><p>&nbsp;</p><p>Ertugliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean steady-state volume of distribution of ertugliflozin following an intravenous dose is 86 l. Plasma protein binding of ertugliflozin is 93.6% and is independent of ertugliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment. The blood-to-plasma concentration ratio of ertugliflozin is 0.66.</p><p>&nbsp;</p><p>Ertugliflozin is not a substrate of organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or organic anion transporting polypeptides (OATP1B1, OATP1B3) <em>in vitro.</em></p><p><em>&nbsp;</em></p><p><u>Biotransformation</u></p><p>Metabolism is the primary clearance mechanism for ertugliflozin. The major metabolic pathway for ertugliflozin is UGT1A9 and UGT2B7-mediated O-glucuronidation to two glucuronides that are pharmacologically inactive at clinically relevant concentrations. CYP-mediated (oxidative) metabolism of ertugliflozin is minimal (12%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean systemic plasma clearance following an intravenous 100 &micro;g dose was 11 l/hr. The mean elimination half-life in type 2 diabetic patients with normal renal function was estimated to be</p><p>17 hours based on the population pharmacokinetic analysis. Following administration of an oral [14C]-ertugliflozin solution to healthy subjects, approximately 41% and 50% of the drug-related</p><p>radioactivity was eliminated in faeces and urine, respectively. Only 1.5% of the administered dose was excreted as unchanged ertugliflozin in urine and 34% as unchanged ertugliflozin in faeces, which is likely due to biliary excretion of glucuronide metabolites and subsequent hydrolysis to parent.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In a Phase 1 clinical pharmacology study in patients with type 2 diabetes and mild, moderate, or severe renal impairment (as determined by eGFR), following a single-dose administration of 15 mg ertugliflozin, the mean increases in AUC of ertugliflozin were &le; 1.7-fold, compared to subjects with</p><p>&nbsp;</p><p>normal renal function. These increases in ertugliflozin AUC are not considered clinically relevant. There were no clinically meaningful differences in the ertugliflozin Cmax&nbsp;values among the different renal function groups. The 24-hour urinary glucose excretion declined with increasing severity of renal impairment (see section 4.4). The plasma protein binding of ertugliflozin was unaffected in patients with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Moderate hepatic impairment (based on the Child-Pugh classification) did not result in an increase in exposure of ertugliflozin. The AUC of ertugliflozin decreased by approximately 13%, and Cmax&nbsp;decreased by approximately 21% compared to subjects with normal hepatic function. This decrease in ertugliflozin exposure is not considered clinically meaningful. There is no clinical experience in patients with Child-Pugh class C (severe) hepatic impairment. The plasma protein binding of ertugliflozin was unaffected in patients with moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No studies with ertugliflozin have been performed in paediatric patients.</p><p>&nbsp;</p><p><em>Effects of age, body weight, gender and race</em></p><p>Based on a population pharmacokinetic analysis, age, body weight, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of ertugliflozin.</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p>&nbsp;</p><p><u>Absorption</u></p><p>Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose. Mean plasma AUC of sitagliptin was 8.52 mM&bull;hr and Cmax&nbsp;was 950 nM. The absolute bioavailability of sitagliptin is approximately 87%. Since coadministration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, Steglujan may be administered with or without food.</p><p>&nbsp;</p><p>Plasma AUC of sitagliptin increased in a dose-proportional manner. Dose-proportionality was not established for Cmax&nbsp;and C24hr&nbsp;(Cmax&nbsp;increased in a greater than dose-proportional manner and C24hr&nbsp;increased in a less than dose-proportional manner).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 l. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway. Approximately 79% of sitagliptin is excreted unchanged in the urine.</p><p>&nbsp;</p><p>Following a [14C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin. <em>In vitro </em>studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.</p><p>&nbsp;</p><p><em>In vitro </em>data showed that sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following administration of an oral [14C]-sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in faeces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2&nbsp;following a 100-mg oral dose of sitagliptin was approximately</p><p>&nbsp;</p><p>12.4 hours. Sitagliptin accumulates only minimally with multiple doses. The renal clearance was approximately 350 ml/min.</p><p>&nbsp;</p><p>Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established. Sitagliptin is also a substrate of P-gp, which may also be involved in mediating the renal elimination of sitagliptin. However, ciclosporin, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin. Sitagliptin is not a substrate for OCT2 or OAT1 or peptide transporter 1/2 (PEPT1/2) transporters. <em>In vitro</em>, sitagliptin did not inhibit OAT3 (IC50=160 mM) or p-glycoprotein (up to 250 mM) mediated transport at therapeutically relevant plasma concentrations. In a clinical study sitagliptin had a small effect on plasma digoxin concentrations indicating that sitagliptin may be a</p><p>mild inhibitor of P-gp.</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>No drug interactions studies have been performed with Steglujan and other medicinal products; however, such studies have been conducted with the individual active substances.</p><p>&nbsp;</p><p><u>In vitro <em>assessment of ertugliflozin</em></u></p><p>In <em>in vitro </em>studies, ertugliflozin and ertugliflozin glucuronides did not inhibit or inactivate CYPs 1A2, 2C9, 2C19, 2C8, 2B6, 2D6, or 3A4, and did not induce CYPs 1A2, 2B6, or 3A4. Ertugliflozin and ertugliflozin glucuronides did not inhibit the activity of UGTs 1A6, 1A9 or 2B7 <em>in vitro</em>. Ertugliflozin was a weak inhibitor of UGTs 1A1 and 1A4 <em>in</em><em> vitro </em>at higher concentrations that are not clinically relevant. Ertugliflozin glucuronides had no effect on these isoforms. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered drugs eliminated by these enzymes.</p><p>&nbsp;</p><p>Ertugliflozin or ertugliflozin glucuronides do not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 transporters or transporting polypeptides OATP1B1 and OATP1B3 at clinically relevant concentrations <em>in vitro</em>. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are substrates of these transporters.</p><p>&nbsp;</p><p><u>In vitro <em>assessment of sitagliptin</em></u></p><p><em>In vitro </em>data suggest that sitagliptin does not inhibit or induce CYP450 isoenzymes. In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing <em>in vivo </em>evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and OCT. Sitagliptin may be a mild inhibitor of P-gp <em>in vivo</em>.</p><p>&nbsp;</p><p><em>In vitro </em>transport studies showed that sitagliptin is a substrate for P-gp and OAT3. OAT3 mediated transport of sitagliptin was inhibited <em>in vitro </em>by probenecid, although the risk of clinically meaningful interactions is considered to be low. Concomitant administration of OAT3 inhibitors has not been evaluated <em>in vivo</em>.</p><p>&nbsp;</p><p><u>Characteristics in patients</u></p><p>The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin. Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD).</p><p>&nbsp;</p><p>Compared to normal healthy control subjects, plasma AUC of sitagliptin was increased modestly in patients with GFR &ge; 45 to &lt; 90 mL/min. Because increases of this magnitude are not clinically relevant, dosage adjustment in these patients is not necessary.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>No dose adjustment for sitagliptin is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score &pound; 9). There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score &gt; 9). However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required based on age. Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase 1 and Phase 2 data. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.</p><p>&nbsp;</p><p><em>Paediatric</em></p><p>No studies with sitagliptin have been performed in paediatric patients.</p><p>&nbsp;</p><p><em>Other patient characteristics</em></p><p>No dose adjustment is necessary based on gender, race, or body mass index (BMI). These characteristics had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase 1 pharmacokinetic data and on a population pharmacokinetic analysis of Phase 1 and Phase 2 data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute toxicity, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><u>General toxicity</u></p><p>Repeat-dose oral toxicity studies were conducted in mice, rats, and dogs for up to 13, 26, and</p><p>39&nbsp; weeks, respectively. Signs of toxicity that were considered adverse were generally observed at exposures greater than or equal to 77 times the human unbound exposure (AUC) at the maximum recommended human dose (MRHD) of 15 mg/day. Most toxicity was consistent with pharmacology related to urinary glucose loss and included decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism, gluconeogenesis and electrolyte imbalances, and urinary changes such as polyuria, glucosuria, and calciuria. Microscopic changes related to glucosuria and/or calciuria observed only in rodents included dilatation of renal tubules, hypertrophy of zona glomerulosa in adrenal glands (rats), and increased trabecular bone (rats). Except for emesis, there were no adverse toxicity findings in dogs at 379 times the human unbound exposure (AUC) at the MRHD of 15 mg/day.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>In the 2-year mouse carcinogenicity study, ertugliflozin was administered by oral gavage at doses of 5, 15, and 40 mg/kg/day. There were no ertugliflozin-related neoplastic findings at doses up to</p><p>40&nbsp; mg/kg/day (approximately 41 times human unbound exposure at the MRHD of 15 mg/day based on AUC). In the 2-year rat carcinogenicity study, ertugliflozin was administered by oral gavage at doses of 1.5, 5, and 15 mg/kg/day. Ertugliflozin-related neoplastic findings included an increased incidence of benign adrenal medullary pheochromocytoma in male rats at 15 mg/kg/day. This finding was attributed to carbohydrate malabsorption leading to altered calcium homeostasis and was not considered&nbsp;&nbsp; &nbsp;relevant to human risk. The no-observed-effect level (NOEL) for neoplasia was</p><p>5 mg/kg/day (approximately 16 times human unbound exposure at the MRHD of 15 mg/day).</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>Ertugliflozin was not mutagenic or clastogenic with or without metabolic activation in the microbial reverse mutation, <em>in vitro </em>cytogenetic (human lymphocytes), and <em>in</em><em> vivo </em>rat micronucleus assays.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>In the rat fertility and embryonic development study, male and female rats were administered ertugliflozin at 5, 25, and 250 mg/kg/day. No effects on fertility were observed at 250 mg/kg/day (approximately 386 times human unbound exposure at the MRHD of 15 mg/day based on AUC comparisons). Ertugliflozin did not adversely affect developmental outcomes in rats and rabbits at maternal exposures that were 239 and 1,069 times, respectively, the human exposure at the maximum clinical dose of 15 mg/day, based on AUC. At a maternally toxic dose in rats (250 mg/kg/day), lower foetal viability and a higher incidence of a visceral malformation were observed at maternal exposure that was 510 times the maximum clinical dose of 15 mg/day.</p><p>&nbsp;</p><p>In the pre- and post-natal development study, decreased post-natal growth and development were observed in rats administered ertugliflozin gestation day 6 through lactation day 21 at</p><p>&ge; 100 mg/kg/day (estimated 239 times the human exposure at the maximum clinical dose of</p><p>15 mg/day, based on AUC). Sexual maturation was delayed in both sexes at 250 mg/kg/day (estimated 620 times the MRHD at 15 mg/day, based on AUC).</p><p>&nbsp;</p><p>When ertugliflozin was administered to juvenile rats from post-natal day (PND) 21 to PND 90, a</p><p>period of renal development corresponding to the late second and third trimesters of human pregnancy, increased kidney weights, dilatation of the renal pelvis and tubules, and renal tubular mineralization were seen at an exposure 13 times the maximum clinical dose of 15 mg/day, based on AUC. Effects</p><p>on bone (shorter femur length, increased trabecular bone in the femur) as well as effects of delayed puberty were observed at an exposure 817 times the MRHD of 15 mg/day based on AUC. The effects on kidney and bone did not fully reverse after the 1 month recovery period.</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p>Renal and liver toxicity were observed in rodents at systemic exposure values 58 times the human exposure level, while the no-effect level was found at 19 times the human exposure level. Incisor teeth abnormalities were observed in rats at exposure levels 67 times the clinical exposure level; the</p><p>no-effect level for this finding was 58-fold based on the 14-week rat study. The relevance of these findings for humans is unknown. Transient treatment-related physical signs, some of which suggest neural toxicity, such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed in dogs at exposure levels approximately</p><p>23 times the clinical exposure level. In addition, very slight to slight skeletal muscle degeneration was also observed histologically at doses resulting in systemic exposure levels of approximately 23 times the human exposure level. A no-effect level for these findings was found at an exposure 6-fold the clinical exposure level.</p><p>&nbsp;</p><p>Sitagliptin has not been demonstrated to be genotoxic in preclinical studies. Sitagliptin was not carcinogenic in mice. In rats, there was an increased incidence of hepatic adenomas and carcinomas at systemic exposure levels 58 times the human exposure level. Since hepatotoxicity has been shown to correlate with induction of hepatic neoplasia in rats, this increased incidence of hepatic tumours in rats was likely secondary to chronic hepatic toxicity at this high dose. Because of the high safety margin (19-fold at this no-effect level), these neoplastic changes are not considered relevant for the situation in humans.</p><p>&nbsp;</p><p>No adverse effects upon fertility were observed in male and female rats given sitagliptin prior to and throughout mating.</p><p>&nbsp;</p><p>In a pre-/post-natal development study performed in rats sitagliptin showed no adverse effects.</p><p>&nbsp;</p><p>Reproductive toxicity studies showed a slight treatment-related increased incidence of foetal rib malformations (absent, hypoplastic and wavy ribs) in the offspring of rats at systemic exposure levels more than 29 times the human exposure levels. Maternal toxicity was seen in rabbits at more than</p><p>29 times the human exposure levels. Because of the high safety margins, these findings do not suggest a relevant risk for human reproduction. Sitagliptin is secreted in considerable amounts into the milk of lactating rats (milk/plasma ratio: 4:1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Microcrystalline cellulose (E460)</p><p>Calcium hydrogen phosphate (anhydrous) Croscarmellose sodium</p><p>Sodium stearyl fumarate (E487)</p><p>Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Tablet coat</u></p><p>Hypromellose (E464)</p><p>Hydroxypropyl cellulose (E463)</p><p>Titanium dioxide (E171)</p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172) Iron oxide black (E172) Carnauba wax (E903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 300C.&nbsp; Store in the original package</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/PVC/PA/Alu blisters Packs of 14, 28, 30, 84, 90 and 98 film-coated tablets in non-perforated blisters. Packs of 30x1 film-coated tablets in perforated unit dose blisters.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder:
Merck Sharp & Dohme B.V.
Waarderweg 
2031 BN Haarlem 
The Netherlands


Manufacturer:
Schering-Plough Labo NV 
Industriepark 30
Heist-op-den-berg, B-2220
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>